• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (43)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Public Health  • Tobacco  • Quality of Care  • Evidence-Based Medicine  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Literature Review and a Meta-analysis

Jean-François Etter, PhD, MPH

Arch Intern Med. 2006;166:1553-1559.

Background  Cytisine is an agonist of nicotinic receptors; in particular, it binds strongly with ₄₂ nicotinic receptors. Cytisine has been used to treat tobacco dependence for 40 years in Eastern Europe. The objective of this study was to review the literature on the effect of cytisine on smoking cessation.

Methods  Review of PubMed, EMBASE, Psychological Abstracts, BIOSIS, Google.com, and Scholar.google.com, using the keywords cytisine, cytisin, zytisin, cytisinum, Tabex, and smoking cessation. Experts and the manufacturer of Tabex were contacted. Placebo-controlled trials were included in a meta-analysis.

Results  Ten studies reported the effects of cytisine on smoking cessation, including 4 controlled studies (3 placebo controlled). Nine studies used the Bulgarian drug Tabex, containing 1.5 mg of cytisine per tablet, and one Russian study used buccal films containing either 1.5 mg of cytisine or 0.75 mg of cytisine plus 0.75 mg of anabasine. All studies were published between 1967 and 2005 in Bulgaria, Germany, Poland, and Russia. There were 4404 smokers treated with cytisine and 3518 in control conditions. The pooled odds ratio after 3 to 8 weeks in the 3 placebo-controlled trials (2 were double blind and 1 was randomized) was 1.93 (95% confidence interval, 1.21-3.06). For the 2 placebo-controlled double-blind trials with a longer follow-up, the pooled odds ratio after 3 to 6 months was 1.83 (95% confidence interval, 1.12-2.99). One placebo-controlled double-blind trial had follow-up after 2 years (odds ratio, 1.77; 95% confidence interval, 1.29-2.43). Some adverse effects were reported. Most trials were, however, of poor quality.

Conclusions  Cytisine may be effective for smoking cessation. This fact remained largely unnoticed in the English-language literature.

Author Affiliation: Institute of Social and Preventive Medicine, University of Geneva, Geneva, Switzerland.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

New Weapon to Curb Smoking: No More Excuses to Delay Treatment
Bankole A. Johnson
Arch Intern Med. 2006;166(15):1547-1550.
EXTRACT | FULL TEXT  

Smoking Cessation With Varenicline, a Selective 42 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
Mitchell Nides, Cheryl Oncken, David Gonzales, Stephen Rennard, Eric J. Watsky, Rich Anziano, Karen R. Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1561-1568.
ABSTRACT | FULL TEXT  

Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation
Cheryl Oncken, David Gonzales, Mitchell Nides, Stephen Rennard, Eric Watsky, Clare B. Billing, Richard Anziano, Karen Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1571-1577.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cytisine's Potential to Be Used as a Traditional Healing Method to Help Indigenous People Stop Smoking: A Qualitative Study With Mori
Thompson-Evans et al.
Nicotine Tob Res 2011;13:353-360.
ABSTRACT | FULL TEXT  

Review: Nicotinic receptors and stages of nicotine dependence
Brennan et al.
J Psychopharmacol 2010;24:793-808.
ABSTRACT  

Smoking Cessation
Chandler and Rennard
Chest 2010;137:428-435.
ABSTRACT | FULL TEXT  

Smoking cessation pharmacotherapy
Frishman
Ther Adv Cardiovasc Dis 2009;3:287-308.
ABSTRACT  

Cytisine-Based Nicotinic Partial Agonists as Novel Antidepressant Compounds
Mineur et al.
J. Pharmacol. Exp. Ther. 2009;329:377-386.
ABSTRACT | FULL TEXT  

Pharmacological treatments for tobacco dependence
Fagerstrom and Jimenez-Ruiz
Eur Respir Rev 2008;17:192-198.
ABSTRACT | FULL TEXT  

Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal
De Biasi and Salas
Exp Biol Med 2008;233:917-929.
ABSTRACT | FULL TEXT  

Varenicline: The newest agent for smoking cessation
Potts and Garwood
Am J Health Syst Pharm 2007;64:1381-1384.
ABSTRACT | FULL TEXT  

Evidently. . .
Lehman
Evid. Based Med. 2007;12:8-8.
FULL TEXT  

Other articles noted
Evid. Based Med. 2007;12:31-32.
FULL TEXT  

Another Arrow in the Quiver to Combat Smoking
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT  

New Weapon to Curb Smoking: No More Excuses to Delay Treatment.
Johnson
Arch Intern Med 2006;166:1547-1550.
FULL TEXT